result
inconsist
regard
impact
uric
acid
ua
clinic
outcom
gener
popul
patient
chronic
kidney
diseas
aim
studi
studi
influenc
serum
ua
level
mortal
patient
undergo
continu
ambulatori
periton
dialysi
method
data
patient
singl
periton
dialysi
unit
retrospect
analyz
mean
age
patient
year
femal
n
concomit
comorbid
start
continu
ambulatori
periton
dialysi
capd
encompass
diabet
mellitu
n
hypertens
n
cardiovascular
diseas
n
studi
cohort
divid
sexspecif
tertil
accord
baselin
ua
level
cox
proport
hazard
model
use
calcul
hazard
ratio
hr
allcaus
cardiovascular
infectionassoci
mortal
adjust
demograph
laboratori
data
medic
comorbid
result
multivari
cox
regress
analysi
show
use
ua
tertil
refer
adjust
hr
allcaus
cardiovascular
infectionassoci
mortal
tertil
confid
interv
ci
p
ci
p
ci
p
fulli
adjust
model
adjust
hr
allcaus
cardiovascular
infectionassoci
mortal
increas
ua
level
ci
p
ci
p
ci
p
men
ci
p
ci
p
ci
p
women
respect
conclus
higher
ua
level
associ
lower
risk
allcaus
cardiovascular
infectionassoci
mortal
women
treat
continu
ambulatori
periton
dialysi
uric
acid
ua
final
product
purin
metabol
gener
xanthin
oxidas
xanthin
dehydrogenas
human
rather
ingest
uric
acid
mainli
produc
liver
metabol
endogen
exogen
purin
product
approxim
twothird
daili
produc
ua
excret
function
kidney
rest
larg
excret
gastrointestin
tract
elev
ua
significantli
associ
rapid
kidney
function
declin
incid
chronic
kidney
diseas
ckd
jackson
heart
studi
african
american
therefor
hyperuricemia
frequent
encount
patient
renal
failur
particularli
advanc
chronic
kidney
diseas
ckd
burden
healthcar
system
caus
chronic
kidney
diseas
ckd
increas
worldwid
patient
ckd
includ
requir
hemodialysi
periton
dialysi
highrisk
cardiovascular
cv
event
approxim
patient
death
due
cardiovascular
diseas
cvd
annual
current
literatur
equivoc
regard
role
ua
predict
risk
cardiovascular
diseas
mortal
epidemiolog
studi
identifi
associ
uric
acid
cvd
well
mortal
gener
popul
ckd
patient
studi
report
associ
independ
may
attribut
concomit
cardiovascular
risk
factor
hyperglycemia
hypertens
insulin
resist
given
ua
potenti
modifi
risk
factor
clarifi
effect
clinic
outcom
may
chang
healthcar
polici
date
hand
studi
investig
associ
ua
mortal
patient
endstag
renal
diseas
esrd
treat
dialysi
therefor
purpos
present
studi
investig
possibl
link
ua
mortal
patient
undergo
continu
ambulatori
periton
dialysi
capd
adjust
varieti
crucial
variabl
addit
also
evalu
possibl
differ
sex
regard
associ
ua
mortal
studi
carri
retrospect
singl
periton
dialysi
pd
center
changhua
christian
hospit
taiwan
januari
decemb
patient
start
capd
renal
replac
therapi
esrd
screen
studi
enrol
criteria
includ
incid
patient
least
year
age
surviv
capd
least
month
elig
patient
follow
date
commenc
capd
end
studi
decemb
clinic
outcom
censor
cvd
infect
two
lead
caus
death
patient
therefor
primari
outcom
interest
allcaus
mortal
second
outcom
interest
cv
infectionassoci
mortal
cv
mortal
defin
death
attribut
follow
cardiovascular
event
coronari
event
cardiomyopathi
cardiac
dysrhythmia
sudden
cardiac
death
congest
heart
failur
ischem
brain
injuri
cerebrovascular
accid
peripher
vascular
diseas
infect
caus
death
patient
directli
die
sepsi
caus
death
determin
review
discharg
diagnosi
hospit
summari
electron
medic
record
studi
protocol
approv
institut
review
board
hospit
studi
conduct
complianc
declar
helsinki
baselin
characterist
whole
cohort
obtain
hospit
electron
databas
demograph
clinic
data
record
initi
pd
includ
age
sex
statu
pd
predialysi
ckd
hemodialysi
fail
renal
transplant
bodi
mass
index
bmi
medic
comorbid
smoke
statu
comorbid
includ
diabet
mellitu
dm
hypertens
cvd
charlson
comorbid
index
one
commonli
use
score
system
predict
risk
mortal
blood
test
consist
white
blood
cell
wbc
count
hemoglobin
total
cholesterol
triglycerid
calcium
phosphat
alkalin
phosphat
alp
uric
acid
glutamicpyruv
transaminas
gpt
intact
parathyroid
hormon
ipth
ferritin
transferrin
satur
serum
albumin
blood
urea
nitrogen
bun
creatinin
check
laboratori
changhua
christian
hospit
use
medic
record
base
prescript
includ
angiotensinconvert
enzym
ace
inhibitor
angiotensin
ii
receptor
blocker
arb
hypouricem
agent
allopurinol
erythropoiesi
stimul
agent
esa
loop
diuret
furosemid
calcium
channel
blocker
ccb
vitamin
statin
inform
pdrelat
paramet
includ
daili
ultrafiltr
total
ktv
urea
residu
renal
function
rrf
daili
urin
volum
normal
protein
nitrogen
appear
npna
dialysatetoplasma
creatinin
ratio
dp
creatinin
h
rrf
millilit
per
minut
per
deriv
averag
valu
creatinin
urea
clearanc
standard
bodi
surfac
area
patient
classifi
sexspecif
tertil
accord
serum
ua
level
men
tertil
mgdl
tertil
mgdl
tertil
mgdl
women
tertil
mgdl
tertil
mgdl
tertil
mgdl
summari
statist
present
mean
standard
deviat
sd
continu
variabl
normal
distribut
median
interquartil
rang
iqr
continu
variabl
skew
distribut
number
n
percentag
categor
variabl
unless
otherwis
indic
differ
categor
variabl
among
three
group
test
use
chisquar
test
fisher
exact
test
continu
data
normal
distribut
compar
analysi
varianc
anova
skew
continu
data
kruskalw
test
multivari
linear
regress
analysi
backward
elimin
procedur
remov
criterion
probabl
fdistribut
use
evalu
associ
clinic
paramet
baselin
ua
estim
expect
chang
serum
ua
level
relat
chang
signific
clinic
paramet
associ
ua
outcom
interest
evalu
use
cox
proport
hazard
model
construct
use
five
level
adjust
model
adjust
sex
age
statu
pd
smoke
statu
bmi
model
adjust
model
covari
plu
medic
model
adjust
model
covari
plu
comorbid
model
adjust
model
covari
plu
pdrelat
paramet
model
adjust
model
covari
plu
laboratori
data
result
shown
hazard
ratio
hr
confid
interv
ci
strengthen
find
conduct
three
sensit
test
first
cox
regress
analysi
repeat
ua
continu
variabl
hr
present
per
increas
serum
ua
level
sex
second
patient
dichotom
either
hyperuricemia
normouricemia
group
sex
examin
relationship
hyperuricemia
mortal
hyperuricemia
defin
ua
level
mgdl
men
mgdl
women
third
relationship
ua
mortal
calcul
exclud
patient
take
allopurinol
entri
studi
mitig
confound
effect
hypouricem
agent
serum
ua
level
addit
also
perform
stratifi
analys
nutrit
marker
includ
bmi
cholesterol
albumin
npna
phosphoru
creatinin
statist
signific
set
p
valu
analysi
statist
analys
conduct
use
ibm
spss
statist
window
version
ibm
corp
armonk
ny
usa
four
hundr
ninetytwo
capd
patient
enrol
studi
median
followup
period
month
studi
particip
commenc
capd
first
renal
replac
therapi
ie
predialysi
statu
baselin
patient
characterist
accord
sexspecif
tertil
ua
shown
tabl
mean
age
patient
year
femal
n
concomit
comorbid
start
capd
encompass
diabet
mellitu
n
hypertens
n
cardiovascular
diseas
n
median
ua
level
iqr
mgdl
patient
men
significantli
higher
ua
level
women
mgdl
vs
mgdl
respect
p
total
particip
take
hypouricem
agent
allopurinol
baselin
one
hundr
twentyseven
patient
die
studi
period
includ
cardiovascular
diseas
infect
shown
figur
allcaus
mortal
rate
show
stepwis
decreas
ua
tertil
ua
tertil
respect
p
associ
ua
tertil
allcaus
mortal
cox
regress
analysi
shown
tabl
compar
ua
tertil
ua
tertil
associ
lower
risk
overal
mortal
fulli
adjust
model
model
adjust
hr
ahr
ci
p
ua
tertil
associ
lower
risk
overal
mortal
fulli
adjust
model
model
adjust
hr
ahr
ci
p
crude
analysi
allcaus
mortal
rate
sexspecif
tertil
serum
uric
acid
level
p
shown
figur
cv
mortal
rate
show
stepwis
decreas
ua
tertil
ua
tertil
respect
p
associ
ua
tertil
cv
mortal
shown
tabl
use
ua
tertil
refer
ahr
ua
tertil
ci
p
respect
cv
mortal
shown
figur
cv
mortal
rate
show
stepwis
decreas
ua
tertil
ua
tertil
respect
p
associ
ua
tertil
cv
mortal
shown
tabl
use
ua
tertil
refer
ahr
ua
tertil
ci
p
respect
cv
mortal
crude
analysi
cardiovascular
mortal
rate
sexspecif
tertil
serum
uric
acid
level
p
shown
figur
infectionassoci
mortal
rate
show
stepwis
decreas
ua
tertil
ua
tertil
respect
p
associ
ua
tertil
infectionassoci
mortal
shown
tabl
statist
signific
differ
risk
infectionassoci
mortal
among
ua
tertil
shown
figur
infectionassoci
mortal
rate
show
stepwis
decreas
ua
tertil
ua
tertil
respect
p
associ
ua
tertil
infectionassoci
mortal
shown
tabl
statist
signific
differ
risk
infectionassoci
mortal
among
ua
tertil
figur
cv
mortal
rate
show
stepwis
decreas
ua
tertil
ua
tertil
respect
p
associ
ua
tertil
cv
mortal
shown
tabl
use
ua
tertil
refer
ahr
ua
tertil
ci
p
respect
cv
mortal
crude
analysi
cardiovascular
mortal
rate
sexspecif
tertil
serum
uric
acid
level
p
shown
figur
infectionassoci
mortal
rate
show
stepwis
decreas
ua
tertil
ua
tertil
respect
p
associ
ua
tertil
infectionassoci
mortal
shown
tabl
statist
signific
differ
risk
infectionassoci
mortal
among
ua
tertil
also
evalu
relationship
mortal
ua
nonsexspecif
tertil
shown
tabl
higher
ua
level
associ
lower
risk
allcaus
cv
infectionassoci
mortal
tabl
cox
regress
model
allcaus
cardiovascular
infect
associ
mortal
uric
acid
nonsexspecif
tertil
similar
associ
ua
mortal
note
treat
ua
continu
variabl
tabl
fulli
adjust
model
ahr
allcaus
cv
infect
associ
mortal
higher
ua
level
ci
p
ci
p
ci
p
men
ci
p
ci
p
ci
p
women
respect
exclud
patient
receiv
allopurinol
treatment
signific
associ
remain
women
men
tabl
base
predefin
sexspecif
ua
level
classifi
patient
hyperuricem
nonhyperuricem
hyperuricemia
clearli
correl
lower
risk
overal
mortal
cv
mortal
infectionassoci
mortal
women
men
tabl
list
signific
associ
ua
clinic
paramet
baselin
multivari
linear
regress
analysi
serum
ua
level
posit
correl
male
gender
albumin
bun
ipth
phosphoru
triglycerid
cv
diseas
residu
renal
function
neg
correl
age
urin
output
tabl
show
result
stratifi
analys
bmi
cholesterol
albumin
npna
phosphoru
creatinin
median
valu
paramet
use
divid
entir
cohort
two
subgroup
nearli
p
valu
interact
show
nonsignific
result
indic
signific
interact
effect
ua
nutrit
marker
studi
examin
associ
ua
allcaus
cv
infectionassoci
mortal
risk
singl
pd
center
taiwan
major
find
studi
higher
ua
level
ua
tertil
associ
lower
risk
allcaus
cv
infectionassoci
mortal
femal
esrd
patient
treat
capd
independ
sever
confound
factor
observ
verifi
similar
result
note
ua
treat
dichotom
continu
variabl
furthermor
associ
remain
signific
exclud
patient
take
hypouricem
agent
find
contrast
previous
publish
studi
pd
patient
impli
hyperuricemia
per
se
may
protect
risk
mortal
pd
patient
date
investig
evalu
impact
ua
mortal
pd
patient
one
studi
conduct
sweden
compris
subject
start
renal
replac
therapi
start
periton
dialysi
rest
start
hemodialysi
patient
evalu
whole
mean
followup
month
patient
chang
initi
dialysi
modal
major
hemodialysi
end
studi
conclud
ua
show
jshape
relationship
allcaus
mortal
greatest
risk
quintil
anoth
retrospect
studi
involv
pd
subject
conduct
china
exclud
pd
durat
less
month
histori
kidney
transplant
cirrhosi
ua
level
check
start
periton
dialysi
month
follow
pd
analysi
mortal
also
demonstr
jshape
uamort
associ
higher
serum
ua
level
independ
risk
factor
allcaus
mortal
pd
patient
later
xia
et
al
conduct
larg
investig
pd
patient
south
china
found
elev
level
ua
independ
risk
factor
allcaus
cv
mortal
men
women
treat
pd
therefor
associ
ua
mortal
may
larg
influenc
gender
howev
multicent
studi
patient
chronic
pd
china
report
contrast
result
prognost
valu
ua
allcaus
cv
mortal
weaken
disappear
adjust
uremiarel
tradit
cv
risk
factor
recent
ua
report
predictor
cardiovascular
mortal
male
pd
patient
diabet
reason
differ
impact
ua
patient
surviv
male
femal
patient
yet
clarifi
may
due
patient
ethnic
differ
followup
period
differ
adjust
confound
differ
serum
ua
level
men
women
studi
report
signific
relationship
ua
cv
mortal
women
men
longer
followup
period
previou
studi
cohort
report
associ
mere
women
sex
hormon
may
also
result
differ
result
men
women
estradiol
progesteron
testosteron
report
affect
ua
transport
mice
kidney
serum
ua
level
report
higher
postmenopaus
premenopaus
women
furthermor
differ
sex
may
also
indic
women
suscept
uaassoci
damag
men
evidenc
studi
arteri
stiff
silent
brain
infarct
intern
carotid
arteri
resist
index
howev
exact
reason
relationship
remain
clarifi
contradictori
result
relat
ua
outcom
partli
attribut
dual
effect
ua
cv
outcom
sever
mechan
propos
explain
detriment
effect
ua
first
hyperuricemia
close
relat
establish
convent
cardiovascular
risk
factor
dm
hypertens
older
age
male
gender
increas
evid
show
ua
may
caus
kidney
diseas
hypertens
high
oxid
stress
metabol
syndrom
second
ua
lead
endotheli
dysfunct
induc
hypertens
activ
reninangiotensin
system
ua
caus
rheolog
disturb
increas
platelet
aggreg
adhes
third
hyperuricemia
report
acceler
residu
renal
function
declin
strong
predictor
patient
mortal
pd
patient
hand
four
possibl
explan
may
explain
lower
ua
level
associ
higher
mortal
rate
first
serum
ua
level
may
reflect
nutrit
statu
major
sourc
ua
deriv
dietari
intak
purin
nucleotid
therefor
low
serum
ua
may
indic
malnourish
statu
turn
account
suscept
sepsi
impair
immun
function
studi
abl
show
low
ua
associ
potenti
biomark
proteinenergi
wast
low
level
serum
albumin
phosphat
presenc
malnutrit
protein
wast
often
accompani
increas
inflamm
oxid
stress
link
high
risk
mortal
esrd
patient
second
vivo
vitro
experi
ua
shown
power
free
radic
scaveng
could
benefit
cv
system
third
socal
revers
epidemiolog
also
known
risk
factor
revers
complet
exclud
factor
tradit
consid
harm
indic
gener
popul
may
associ
benefici
effect
clinic
outcom
variou
chronic
diseas
obes
paradox
esrd
mani
possibl
confound
risk
factor
adjust
analysi
paradox
associ
low
ua
level
high
mortal
remain
signific
studi
fourth
lack
data
creactiv
protein
due
retrospect
natur
studi
unknown
whether
result
remain
consist
creactiv
protein
incorpor
analysi
fifth
inflammatori
cytokin
appear
caus
low
ua
result
impair
net
renal
tubular
reabsorpt
urat
taiwanes
studi
patient
sever
acut
respiratori
syndrom
show
mark
renal
hypouricemia
due
defect
renal
ua
handl
associ
higher
serum
level
howev
hypothesi
may
affect
esrd
patient
great
extent
due
small
residu
renal
function
measur
renal
fraction
excret
ua
studi
strength
studi
includ
mediums
popul
capd
patient
sinc
detail
inform
collect
regard
patient
demograph
featur
comorbid
medic
laboratori
data
abl
conduct
comprehens
analysi
minim
potenti
bia
observ
studi
potenti
limit
present
studi
nonetheless
mention
first
patient
recruit
singl
pd
center
thu
allow
gener
result
entir
popul
capd
patient
due
divers
differ
cultur
demograph
factor
second
residu
confound
factor
complet
exclud
exampl
insulin
resist
shown
predictor
cardiovascular
mortal
esrd
patient
evalu
studi
third
due
retrospect
natur
studi
unabl
determin
whether
low
ua
level
contribut
reduc
antioxid
capac
whether
ua
per
se
caus
factor
mere
marker
nutrit
inflamm
oxid
stress
answer
studi
fourth
singl
measur
ua
baselin
cover
acut
chang
ua
studi
period
might
underestim
overestim
true
relationship
studi
outcom
despit
limit
believ
studi
contribut
rather
limit
knowledg
predict
valu
ua
capd
patient
conclus
found
invers
relationship
ua
level
allcaus
cv
infectionassoci
mortal
femal
patient
capd
base
find
benefici
impact
associ
ua
appear
outweigh
harm
effect
may
thu
protect
role
capd
patient
signific
associ
alert
clinician
pay
attent
women
capd
low
ua
level
ua
paradox
may
explain
associ
low
level
ua
poor
nutrit
possibl
increas
oxid
stress
howev
whether
low
level
ua
caus
consequ
condit
remain
elucid
prospect
studi
larger
sampl
size
need
confirm
relationship
clarifi
underli
mechan
role
ua
antioxid
capac
